...
首页> 外文期刊>Journal of Cancer Research and Therapeutics >Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer
【24h】

Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer

机译:KI-67的预后和临床病理值和初级PT1尿路上皮癌中的免疫组化表达

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To investigate the prognostic and clinicopathologic value of Ki-67 and profilin 1 immunohistochemical expression in primary pT1 papillary urothelial bladder cancer. Materials and Methods: This study included 88 male and 13 female pT1 primary bladder cancer patients. Demographic characteristics, tumor histological grade, tumor number, presence of concomitant carcinoma in situ, tumor size, and status of recurrence or progression were recorded for each patient. Expression of Ki-67 and profilin 1 was evaluated by immunohistochemical analysis of paraffin-embedded tumor tissues. The Pearson's Chi-square test was used for the analysis of qualitative data, and the Kaplan–Meier method and the log-rank test were used for the survival analysis. Results: In the mean follow-up period of 52 months, 52 (51.5%) patients experienced recurrence, 24 (23.8%) patients experienced progression, and 17 (16.8%) patients died from bladder cancer-related causes. Ki-67 expression was significantly associated with tumor histological grade (P = 0.001). In multivariate analysis, Ki-67 positivity had significantly worse outcome for recurrence (P = 0.006) and mortality (P = 0.022). Ki-67-positive (Ki-67 index ≥15%) patients had shorter recurrence-free (P = 0.003), progression-free (P = 0.002), and cancer-specific (P = 0.003) survival. However, no statistically significant relationship was found between profilin 1 expression and clinicopathologic features and prognosis. Conclusions: Ki-67 is a highly predictive biomarker for recurrence-free, progression-free, and cancer-specific survival in pT1 bladder cancer patients, in whom prediction of recurrence and progression are difficult. Ki-67 expression can be safely combined with other prognostic factors. However, in pT1 bladder cancer patients, no significant relationship was found between profilin 1 expression and tumor characteristics or prognostic parameters.
机译:目的:探讨KI-67的预后和临床病理值和初级PT1乳头状尿道尿道癌中的免疫组化学表达。材料和方法:本研究包括88名雄性和13例雌性PT1原发性膀胱癌患者。对每个患者记录了每个患者的人群特征,肿瘤组织学等级,肿瘤数,伴随癌的存在,肿瘤大小和再现或进展的状态。通过石蜡包埋的肿瘤组织的免疫组化分析评价了KI-67和Profilin 1的表达。 Pearson的Chi-Square试验用于分析定性数据,并且Kaplan-Meier方法和对数秩检验用于存活分析。结果:在平均随访时间为52个月,52例(51.5%)患者经历了复发,24例(23.8%)患者经历了进展,17例(16.8%)患者与膀胱癌相关的导致死亡。 KI-67表达与肿瘤组织学等级显着相关(P = 0.001)。在多变量分析中,Ki-67阳性显着较差的再现(p = 0.006)和死亡率(p = 0.022)。 KI-67阳性(KI-67指数≥15%)患者的复发较短(P = 0.003),无进展(P = 0.002)和癌症特异性(P = 0.003)存活率。然而,在毛细血管1表达和临床病理特征和预后没有发现统计学上显着的关系。结论:KI-67是一种高度预测的生物标志物,用于PT1膀胱癌患者的复发,无进展和癌症特异性生存率,难以预测复发和进展的预测。 KI-67表达可以安全地与其他预后因素相结合。然而,在PT1膀胱癌患者中,在素质1表达和肿瘤特征或预后参数之间没有发现显着的关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号